Abstract: A set of serum metabolic biomarkers and detection kit for detecting tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0/14:0/0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1/12:0), Raffinose, LysoPC(20:1(11Z)/0:0), LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0), PC(18:1(9Z)e/2:0), Torvoside G(TG(15:0/15:0/15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0/16:0), NADP, TG(20:0/20:0/20:1(11Z)). The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The tuberculosis detection model based on the levels of the 17 metabolic biomarkers can achieve an area under the ROC curve of 99.5%, sensitivity of 98.2%, and specificity of 95.8% in detecting tuberculosis.

Abstract: A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.

Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.

Abstract: A compound represented by general formula (I) or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An application of the compound of general formula (I) in preparation of drugs for treating and/or preventing she-mediated diseases, especially an application in preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes, diabetes complications, diabetes-related diseases, fibrotic diseases, neurological and mental diseases, pain, and ulcer diseases, etc.

Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.

Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.

Abstract: The present invention relates to a 2-aminopyrimidine compound shown in formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof, preparation methods for the 2-aminopyrimidine compound, and the pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutical composition comprising the compound. Substituents R1, R2, R3, R4, X, Y, Z, Q, m, and n have meanings given in the description. The present invention further relates to the application of the compound of formula I in the preparation of a medication for treating and/or preventing a malignant hematologic disease and other proliferative diseases.

Abstract: Methods and systems for estimating force and motor torque in a mechatronic system are provided herein. Such methods and system are suited for improved control of small-scale mechatronic system, particularly a syringe, valve, and cartridge loader or door opening/closing mechanism of a diagnostic assay system. The methods can compensate for friction and account for various second-order effects, thereby allowing for more accurate pressure estimation, thereby allowing improved syringe operation. The methods can further allow for improved estimation of force or motor torque to allow for improved control of an actuatable valve interfacing the sample cartridge and cartridge loader or door opening/closing system. Methods of calibrating such systems are also provided.

Abstract: Aspects of the present disclosure include connection mechanisms for a peripheral computing device to connect with a mobile computing device. The peripheral computing device may include a device interface component that defines part of the connection mechanisms, and an electrical connection protrusion extending from the device interface component and configured to insert in a corresponding electrical receptacle of a computing device. The device interface component may also include a magnetically connectable docking member configured to magnetically attract or to be magnetically attracted to a corresponding docking component on the computing device. The device interface component may further include a support rail configured to support the electrical connection protrusion and the magnetically connectable docking member. The support rail may comprise a shoulder configured to define a pivot point to guide connecting the peripheral computing device with the computing device.

Abstract: Aspects of the present disclosure include connection mechanisms for a peripheral computing device to connect with a mobile computing device. The peripheral computing device may include a device interface component that defines part of the connection mechanisms, and an electrical connection protrusion extending from the device interface component and configured to insert in a corresponding electrical receptacle of a computing device. The device interface component may also include a magnetically connectable docking member configured to magnetically attract or to be magnetically attracted to a corresponding docking component on the computing device. The device interface component may further include a support rail configured to support the electrical connection protrusion and the magnetically connectable docking member. The support rail may comprise a shoulder configured to define a pivot point to guide connecting the peripheral computing device with the computing device.

Abstract: Provided are base editors containing a cytidine and a catalytically inactive version of Lachnospiraceae bacterium Cpf1 (LbCpf1). The new base editors have greatly improved editing efficiency and fidelity as compared to Cas9-based base editors, and have different editing windows.

Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.

Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.

Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.

Abstract: The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Abstract: The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Abstract: The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Abstract: The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Abstract: A control system of multi-shaft servo motor comprises a position loop module (400) for receiving a position loop given value and a position feedback value of respective shelves and figuring out a velocity loop given value; a velocity loop module (500) for receiving the velocity loop given value and a velocity feedback value of respective shelves and figuring out a current loop given value; a current loop module (200) for receiving the current loop given value and a current feedback value of respective shelves and outputting a current loop output value; a PWM signal generation module (300) for receiving the current loop output value from the current loop module (200) and generating a PWM signal for controlling respective shelves of the servo motor; and a multi-shaft time sequence control module (700).

Abstract: A hall rotary transformer comprises a rotary transformer stator (1), linear Hall components (3), a PCB (4) and a permanent magnet magnetic ring (5). A ring shape soft iron core (2) is installed on the PCB (4). Plural grooves (8) are uniformly distributed inside the peripheral surface of the ring shape soft iron core (2) and have the same number as the linear Hall components (3). Every linear Hall component (3) is installed in its corresponding groove (8) and soldered on the PCB (4). The magnetic sensitive surface of each linear Hall component (3) is aligned with the magnetic pole surface of the permanent magnet magnetic ring (5) each other. A Hall rotation angle encoder is made of the Hall rotary transformer.